{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:55:10Z","timestamp":1790794510110,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04584-2","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:39:23Z","timestamp":1790786363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4300-3079","authenticated-orcid":false,"given":"Suhrob","family":"Toshev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilfuza","family":"Jalalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulchekhra","family":"Tastanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iroda","family":"Nurmatova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikhtiyor","family":"Latipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortiq","family":"Ismoilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"3","key":"4584_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"4584_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"9","key":"4584_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351.","journal-title":"Lancet Oncol"},{"issue":"7528","key":"4584_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"2","key":"4584_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"7","key":"4584_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4584_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45\u201351.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"4584_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44(2):117\u201322.","journal-title":"J Dermatol"},{"issue":"9","key":"4584_CR9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18632\/oncotarget.323","volume":"2","author":"KT Byrne","year":"2011","unstructured":"Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011;2(9):684\u201394.","journal-title":"Oncotarget"},{"issue":"6","key":"4584_CR10","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow MT, Ozga AJ, Servis RL, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50(6):1498-1512.e5.","journal-title":"Immunity"},{"issue":"223","key":"4584_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.","journal-title":"Sci Transl Med"},{"issue":"4","key":"4584_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250281","volume":"54","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang H, Taylor M, et al. The IFN-\u03b3\u2013CXCL9\/CXCL10\u2013CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54(4):e2250281.","journal-title":"Eur J Immunol"},{"issue":"1","key":"4584_CR13","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1038\/s41598-022-09373-9","volume":"12","author":"CM Failla","year":"2022","unstructured":"Failla CM, Carbone ML, Ram\u00edrez-Moreno IG, et al. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients. Sci Rep. 2022;12(1):5448.","journal-title":"Sci Rep"},{"key":"4584_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.872458","volume":"13","author":"CY Ng","year":"2022","unstructured":"Ng CY, Chiu YC, Chan YP, et al. Skin interstitial fluid and plasma multiplex cytokine analysis reveals IFN-\u03b3 signatures and granzyme B as useful biomarker for activity, severity and prognosis assessment in vitiligo. Front Immunol. 2022;13:872458.","journal-title":"Front Immunol"},{"issue":"1","key":"4584_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97296-2","volume":"11","author":"F Lin","year":"2021","unstructured":"Lin F, Hu W, Xu W, Zhou M, Xu AE. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation. Sci Rep. 2021;11(1):18298.","journal-title":"Sci Rep"},{"issue":"5","key":"4584_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017;76(5):847-855.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4584_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/pr800545q","volume":"8","author":"MK Tuck","year":"2009","unstructured":"Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement. J Proteome Res. 2009;8(1):113\u20137.","journal-title":"J Proteome Res"},{"issue":"1","key":"4584_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1373\/clinchem.2011.165787","volume":"58","author":"SA Halim","year":"2012","unstructured":"Halim SA, Newby LK, Ohman EM. Biomarkers in cardiovascular clinical trials: past, present, future. Clin Chem. 2012;58(1):45\u201353.","journal-title":"Clin Chem"},{"issue":"8","key":"4584_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","volume":"20","author":"JE Lommerts","year":"2021","unstructured":"Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021;20(8):883\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"4584_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","volume":"76","author":"M Larsabal","year":"2017","unstructured":"Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4584_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"19","key":"4584_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194576","volume":"14","author":"N Hermann","year":"2022","unstructured":"Hermann N, Maul LV, Ameri M, Traidl S, Ziadlou R, Papageorgiou K, et al. Clinical presentation and prognostic features in patients with immunotherapy-induced vitiligo-like depigmentation: a monocentric prospective observational study. Cancers (Basel). 2022;14(19):4576.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4584_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206\u201312.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"4584_CR24","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886\u201394.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4584_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519\u201327.","journal-title":"JAMA Oncol"},{"issue":"5","key":"4584_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","volume":"9","author":"JJ Nordlund","year":"1983","unstructured":"Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9(5):689\u201396.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4584_CR27","first-page":"1620","volume":"176","author":"HE Teulings","year":"2017","unstructured":"Teulings HE, Willemsen KJ, Glykofridis I, et al. Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. Br J Dermatol. 2017;176(6):1620\u20133.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4584_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjd.12111","volume":"168","author":"HE Teulings","year":"2013","unstructured":"Teulings HE, Overkamp M, Ceylan E, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol. 2013;168(1):162\u201371.","journal-title":"Br J Dermatol"},{"key":"4584_CR29","doi-asserted-by":"publisher","first-page":"1099108","DOI":"10.3389\/fonc.2022.1099108","volume":"12","author":"H Rao","year":"2023","unstructured":"Rao H, Guo Z, Wen X, Zeng X, Wu L, Huang L. Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: a report of three cases and a pooled analysis of individual patient data. Front Oncol. 2023;12:1099108.","journal-title":"Front Oncol"},{"issue":"5","key":"4584_CR30","first-page":"1097","volume":"86","author":"N van Geel","year":"2022","unstructured":"van Geel N, Lommerts J, Bahadoran P, Wolkerstorfer A, Ezzedine K, Speeckaert R. Assessment of vitiligo disease activity: reliability of the Vitiligo Disease Activity Index and other clinical activity signs. J Am Acad Dermatol. 2022;86(5):1097\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4584_CR31","first-page":"380","volume":"32","author":"R Speeckaert","year":"2023","unstructured":"Speeckaert R, van Geel N. Distinguishing active from stable vitiligo: the need for objective biomarkers. Exp Dermatol. 2023;32(4):380\u20139.","journal-title":"Exp Dermatol"},{"issue":"6","key":"4584_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677\u201383.","journal-title":"Arch Dermatol"},{"issue":"5","key":"4584_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130\u20136.","journal-title":"Ann Oncol"},{"issue":"4","key":"4584_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198(4):569\u201380.","journal-title":"J Exp Med"},{"key":"4584_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"ML Frisoli","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621\u201348.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"4584_CR36","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"JE Harris","year":"2012","unstructured":"Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869\u201376.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"4584_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","volume":"137","author":"JM Richmond","year":"2017","unstructured":"Richmond JM, Bangari DS, Essien KI, et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol. 2017;137(2):350\u20138.","journal-title":"J Invest Dermatol"},{"key":"4584_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"4584_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112811","volume":"14","author":"R Speeckaert","year":"2023","unstructured":"Speeckaert R, Belpaire A, Speeckaert MM, van Geel N. A meta-analysis of chemokines in vitiligo: recruiting immune cells towards melanocytes. Front Immunol. 2023;14:1112811.","journal-title":"Front Immunol"},{"issue":"2","key":"4584_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487\u2013504.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4584_CR41","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2340\/00015555-2080","volume":"95","author":"L Yang","year":"2015","unstructured":"Yang L, Wei Y, Sun Y, et al. Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo. Acta Derm Venereol. 2015;95(6):664\u201370.","journal-title":"Acta Derm Venereol"},{"issue":"450","key":"4584_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","volume":"10","author":"JM Richmond","year":"2018","unstructured":"Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018;10(450):eaam7710.","journal-title":"Sci Transl Med"},{"issue":"2","key":"4584_CR43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","volume":"138","author":"K Boniface","year":"2018","unstructured":"Boniface K, Jacquemin C, Darrigade AS, et al. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J Invest Dermatol. 2018;138(2):355\u201364.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"4584_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"S Cheuk","year":"2017","unstructured":"Cheuk S, Schlums H, Gallais Serezal I, et al. CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity. 2017;46(2):287\u2013300.","journal-title":"Immunity"},{"issue":"11","key":"4584_CR45","first-page":"1667","volume":"31","author":"NF Post","year":"2022","unstructured":"Post NF, Luiten RM, Wolkerstorfer A, Bekkenk MW, B\u00f6hm M. Mechanisms of relapse and long-term memory in vitiligo. Exp Dermatol. 2022;31(11):1667\u201376.","journal-title":"Exp Dermatol"},{"issue":"21","key":"4584_CR46","doi-asserted-by":"crossref","first-page":"13463","DOI":"10.3390\/ijms232113463","volume":"23","author":"R Speeckaert","year":"2022","unstructured":"Speeckaert R, Lambert J, Bulat V, Belpaire A, Speeckaert M, van Geel N. Damage-associated molecular patterns in vitiligo: igniter fuse from oxidative stress to melanocyte loss. Int J Mol Sci. 2022;23(21):13463.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4584_CR47","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","volume":"137","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Voet S, Hoste E, van Geel N. S100B is a potential disease activity marker in nonsegmental vitiligo. J Invest Dermatol. 2017;137(7):1445\u201353.","journal-title":"J Invest Dermatol"},{"key":"4584_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.739413","volume":"9","author":"B Xie","year":"2021","unstructured":"Xie B, Chen R, Wang J, et al. Clinical significance of serum oxidative stress markers to assess disease activity and severity in patients with non-segmental vitiligo. Front Cell Dev Biol. 2021;9:739413.","journal-title":"Front Cell Dev Biol"},{"issue":"22","key":"4584_CR49","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487\u201396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4584_CR50","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2133.2012.11198.x","volume":"167","author":"C Vrijman","year":"2012","unstructured":"Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224\u201335.","journal-title":"Br J Dermatol"},{"issue":"9","key":"4584_CR51","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","volume":"16","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, Speeckaert M, De Schepper S, van Geel N. Biomarkers of disease activity in vitiligo: a systematic review. Autoimmun Rev. 2017;16(9):937\u201345.","journal-title":"Autoimmun Rev"},{"key":"4584_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122430","volume":"14","author":"KC Williams","year":"2023","unstructured":"Williams KC, Gault A, Anderson AE, et al. Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations. Front Immunol. 2023;14:1122430.","journal-title":"Front Immunol"},{"key":"4584_CR53","volume":"145","author":"R Speeckaert","year":"2021","unstructured":"Speeckaert R, Belpaire A, Speeckaert MM, van Geel N. A meta-analysis of the cytokine profile in vitiligo. Cytokine. 2021;145:155312.","journal-title":"Cytokine"},{"key":"4584_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597632","volume":"11","author":"U Sj\u00f6bom","year":"2020","unstructured":"Sj\u00f6bom U, Christenson K, Hellstr\u00f6m A, Nilsson AK. Inflammatory markers in suction blister fluid: a comparative study between interstitial fluid and plasma. Front Immunol. 2020;11:597632.","journal-title":"Front Immunol"},{"issue":"3","key":"4584_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1475-097X.1981.tb00896.x","volume":"1","author":"N Rossing","year":"1981","unstructured":"Rossing N, Worm AM. Interstitial fluid: exchange of macromolecules between plasma and skin interstitium. Clin Physiol. 1981;1(3):275\u201384.","journal-title":"Clin Physiol"},{"issue":"6","key":"4584_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064795","volume":"8","author":"HH Cheng","year":"2013","unstructured":"Cheng HH, Yi HS, Kim Y, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS One. 2013;8(6):e64795.","journal-title":"PLoS One"},{"issue":"2","key":"4584_CR57","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jaci.2015.04.011","volume":"136","author":"G Fornasa","year":"2015","unstructured":"Fornasa G, Tsilingiri K, Caprioli F, et al. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. J Allergy Clin Immunol. 2015;136(2):413\u201322.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"4584_CR58","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1515\/CCLM.2008.170","volume":"46","author":"G Lippi","year":"2008","unstructured":"Lippi G, Blanckaert N, Bonini P, et al. Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories. Clin Chem Lab Med. 2008;46(6):764\u201372.","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"4584_CR59","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1373\/clinchem.2014.228783","volume":"61","author":"C Ellervik","year":"2015","unstructured":"Ellervik C, Vaught J. Preanalytical variables affecting the integrity of human biospecimens in biobanking. Clin Chem. 2015;61(7):914\u201334.","journal-title":"Clin Chem"},{"issue":"20","key":"4584_CR60","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1002\/pmic.200600938","volume":"7","author":"J Kool","year":"2007","unstructured":"Kool J, Reubsaet L, Wesseldijk F, et al. Suction blister fluid as potential body fluid for biomarker proteins. Proteomics. 2007;7(20):3638\u201350.","journal-title":"Proteomics"},{"key":"4584_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613031","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhang G, Su M, et al. Vitiligo skin biomarkers associated with favorable therapeutic response. Front Immunol. 2021;12:613031.","journal-title":"Front Immunol"},{"key":"4584_CR62","volume":"9","author":"A Paganelli","year":"2022","unstructured":"Paganelli A, Diani M, Reggiani Bonetti L, et al. Immunohistochemical markers of disease activity in vitiligo. Front Med (Lausanne). 2022;9:894980.","journal-title":"Front Med (Lausanne)"},{"key":"4584_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/srep19918","volume":"6","author":"ML Clausen","year":"2016","unstructured":"Clausen ML, Slotved HC, Krogfelt KA, Agner T. Tape stripping technique for stratum corneum protein analysis. Sci Rep. 2016;6:19918.","journal-title":"Sci Rep"},{"issue":"1","key":"4584_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78943-6","volume":"10","author":"ML Clausen","year":"2020","unstructured":"Clausen ML, Kezic S, Olesen CM, Agner T. Cytokine concentration across the stratum corneum in atopic dermatitis and healthy controls. Sci Rep. 2020;10(1):21895.","journal-title":"Sci Rep"},{"issue":"7","key":"4584_CR65","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/j.1398-9995.2010.02540.x","volume":"66","author":"S Kezic","year":"2011","unstructured":"Kezic S, O\u2019Regan GM, Yau N, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum. Allergy. 2011;66(7):934\u201340.","journal-title":"Allergy"},{"issue":"12","key":"4584_CR66","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamadermatol.2019.2983","volume":"155","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol. 2019;155(12):1358\u201370.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4584_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48698-w","volume":"9","author":"CM Olesen","year":"2019","unstructured":"Olesen CM, Fuchs CSK, Philipsen PA, et al. Advancement through epidermis using tape stripping technique and reflectance confocal microscopy. Sci Rep. 2019;9(1):12217.","journal-title":"Sci Rep"},{"key":"4584_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01931","volume":"10","author":"A Berekmeri","year":"2019","unstructured":"Berekmeri A, Tiganescu A, Alase AA, Vital E, Stacey M, Wittmann M. Non-invasive approaches for the diagnosis of autoimmune\/autoinflammatory skin diseases\u2014a focus on psoriasis and lupus erythematosus. Front Immunol. 2019;10:1931.","journal-title":"Front Immunol"},{"issue":"18","key":"4584_CR69","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1073\/pnas.1716772115","volume":"115","author":"PP Samant","year":"2018","unstructured":"Samant PP, Prausnitz MR. Mechanisms of sampling interstitial fluid from skin using a microneedle patch. Proc Natl Acad Sci U S A. 2018;115(18):4583\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4584_CR70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s42003-018-0170-z","volume":"1","author":"PR Miller","year":"2018","unstructured":"Miller PR, Taylor RM, Tran BQ, et al. Extraction and biomolecular analysis of dermal interstitial fluid collected with hollow microneedles. Commun Biol. 2018;1:173.","journal-title":"Commun Biol"},{"issue":"5","key":"4584_CR71","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/bios15050301","volume":"15","author":"Y Sprunger","year":"2025","unstructured":"Sprunger Y, Longo J, Saeidi A, Ionescu AM. Bridging blood and skin: biomarker profiling in dermal interstitial fluid (dISF) for minimally invasive diagnostics. Biosensors (Basel). 2025;15(5):301.","journal-title":"Biosensors (Basel)"},{"issue":"12","key":"4584_CR72","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41551-022-00998-9","volume":"7","author":"M Friedel","year":"2023","unstructured":"Friedel M, Thompson IAP, Kasting G, et al. Opportunities and challenges in the diagnostic utility of dermal interstitial fluid. Nat Biomed Eng. 2023;7(12):1541\u201355.","journal-title":"Nat Biomed Eng"},{"issue":"37","key":"4584_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201702243","volume":"29","author":"H Chang","year":"2017","unstructured":"Chang H, Zheng M, Yu X, et al. A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic analysis. Adv Mater. 2017;29(37):1702243.","journal-title":"Adv Mater"},{"key":"4584_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.761562","volume":"9","author":"Y Li","year":"2022","unstructured":"Li Y, Fan X, An X, et al. Urinary proteomics analysis of active vitiligo patients: biomarkers for steroid treatment efficacy prediction and monitoring. Front Mol Biosci. 2022;9:761562.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"4584_CR75","doi-asserted-by":"publisher","first-page":"17989","DOI":"10.1038\/s41598-020-75135-0","volume":"10","author":"C Guan","year":"2020","unstructured":"Guan C, Wei J, Xu X, et al. Urinary metabolomic investigations in vitiligo patients. Sci Rep. 2020;10(1):17989.","journal-title":"Sci Rep"},{"issue":"1","key":"4584_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41368-023-00231-6","volume":"15","author":"L Melguizo-Rodr\u00edguez","year":"2023","unstructured":"Melguizo-Rodr\u00edguez L, Costela-Ruiz VJ, Manzano-Moreno FJ, Ruiz C, Illescas-Montes R. Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation. Int J Oral Sci. 2023;15(1):34.","journal-title":"Int J Oral Sci"},{"issue":"3","key":"4584_CR77","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jaad.2019.10.039","volume":"82","author":"AB Pavel","year":"2020","unstructured":"Pavel AB, Zhou L, Diaz A, et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol. 2020;82(3):690\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4584_CR78","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","volume":"147","author":"H He","year":"2021","unstructured":"He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2021;147(1):199\u2013212.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4584_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09207-z","volume":"7","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Suarez-Farinas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.","journal-title":"Sci Rep"},{"issue":"5","key":"4584_CR80","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/srt.13001","volume":"27","author":"M Olsson Lindvall","year":"2021","unstructured":"Olsson Lindvall M, Angerbj\u00f6rn Ande M, Hansson L, Brorsson AL, Berne B, Lod\u00e9n M, et al. Tape stripping for measurement of psoriasis biomarkers: a review of methodological considerations. Skin Res Technol. 2021;27(5):692\u2013701.","journal-title":"Skin Res Technol"},{"issue":"7","key":"4584_CR81","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320.","journal-title":"J Immunol"},{"key":"4584_CR82","volume-title":"ISO 15189:2022 medical laboratories\u2014requirements for quality and competence","author":"International Organization for Standardization","year":"2022","unstructured":"International Organization for Standardization. ISO 15189:2022 medical laboratories\u2014requirements for quality and competence. Geneva: ISO; 2022."},{"key":"4584_CR83","volume-title":"Evaluation of precision of quantitative measurement procedures; approved guideline (EP05-A3)","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. Evaluation of precision of quantitative measurement procedures; approved guideline (EP05-A3). Wayne, PA: CLSI; 2014."},{"issue":"6","key":"4584_CR84","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595\u20139.","journal-title":"Nat Biotechnol"},{"key":"4584_CR85","first-page":"1519116","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu L, Jin L, et al. Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers. Front Immunol. 2025;16:1519116.","journal-title":"Front Immunol"},{"issue":"10244","key":"4584_CR86","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"11","key":"4584_CR87","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.tibtech.2015.09.001","volume":"33","author":"SK Vashist","year":"2015","unstructured":"Vashist SK, Luppa PB, Yeo LY, Ozcan A, Luong JHT. Emerging technologies for next-generation point-of-care testing. Trends Biotechnol. 2015;33(11):692\u2013705.","journal-title":"Trends Biotechnol"},{"issue":"4","key":"4584_CR88","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41587-019-0045-y","volume":"37","author":"J Kim","year":"2019","unstructured":"Kim J, Campbell AS, de \u00c1vila BE, Wang J. Wearable biosensors for healthcare monitoring. Nat Biotechnol. 2019;37(4):389\u2013406.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4584_CR89","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41587-019-0040-3","volume":"37","author":"J Heikenfeld","year":"2019","unstructured":"Heikenfeld J, Jajack A, Feldman B, et al. Accessing analytes in biofluids for peripheral biochemical monitoring. Nat Biotechnol. 2019;37(4):407\u201319.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"4584_CR90","first-page":"1751","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Vandersichel A, Duponselle J, Delbaere L, Herbelet S, Eleftheriadou V, et al. Digital and artificial-intelligence tools for the assessment of vitiligo: a scoping review. J Eur Acad Dermatol Venereol. 2023;37(9):1751\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"4584_CR91","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","volume":"380","author":"A Rajkomar","year":"2019","unstructured":"Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347\u201358.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04584-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:03:11Z","timestamp":1790791391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04584-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":91,"alternative-id":["4584"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04584-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"17 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}